Clinical Trials
- Women's Health
The EMPOWER Study: Endometriosis Diagnosis Using microRNA (EMPOWER)
- Ages18 years - 49 years
- GenderFemale only
- Date01/03/2022
- Women's Health
Pre-IVF Treatment With a GnRH Antagonist in Women With Endometriosis (PREGnant)
- Ages18 years - 38 years
- GenderFemale only
- Date12/01/2021
- Thyroid and Other Endocrine Cancers, Gynecological Cancers
Endometrium and Metabolism
- Date12/14/2018
- Gynecological Cancers
A Phase 1 Open-Label, Safety, Pharmacokinetic and Preliminary Efficacy Study of STRO-002, an Anti-Folate Receptor Alpha (FolRα) Antibody-Drug Conjugate (ADC), in Patients With Advanced Epithelial Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) and Endometrial Cancers
- GenderFemale only
- Date12/21/2021
- Gynecological Cancers
A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma
- Date02/24/2020
- Women's Health, Pregnancy and Obstetrics
Pharmacokinetics and Hepatic Safety of EGCG
- Ages18 years - 40 years
- GenderFemale only
- Date09/13/2021
- Gynecological Cancers
A Phase II Evaluation of Afatinib
- Ages18 years and younger
- GenderFemale only
- Date05/18/2015
- Breast Cancer
A Randomized Phase II Trial Of Circulating Tumor DNA-Guided Second Line Adjuvant Therapy For High Residual Risk, Stage II-III, Hormone Receptor Positive, HER2 Negative Breast Cancer
- Date08/31/2021
- Brain, Spinal Cord & Nervous System
Multiple Sclerosis: Symptoms and Hormones Study
- Ages18 years - 45 years
- GenderFemale only
- Date04/13/2021
- Gynecological Cancers
A Phase 2 Study of VS-6766 (Dual RAF/MEK Inhibitor) Alone and In Combination With Defactinib (FAK Inhibitor) in Recurrent Low-Grade Serous Ovarian Cancer (LGSOC)
- GenderFemale only
- Date10/21/2021